Several CPT code updates that impact Molecular Pathology became effective January 1, 2015. The following is a brief overview of these updates.

**Molecular Pathology Revisions**

A new column has been added to the Molecular Pathology Gene Table called Claim Designation. This can be used on your claim form in box 19 (or equivalent electronic loop) to specify the analyte tested. This however is not required by Center for Medicare and Medicaid Services (CMS). New definitions have been added in the introductory guidelines and two new subsections of Genomic Sequencing Procedures (GSP) and Other Molecular Multianalyte Assays were added.

**Tier 1 Molecular Pathology:** now contains 110 codes, 3 codes were added and 1 code was revised

- New 82146 FLT3, gene analysis; tyrosine kinase domain (TKD) variants (e.g. D835, I836)
- New 81288 (code out of sequence) MLH1 gene analysis; promoter methylation analysis
- New 81313 PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (e.g. prostate cancer)
- Revised 82145 FLT3 gene analysis, internal tandem duplication (ITD) variants (i.e. exons 14, 15); internal tandem duplication (ITD) variants (i.e. exons 14, 15)

**Tier 2 Molecular Pathology:** 4 code revisions

- Revised 81402 Molecular pathology procedure level 3: analysis added to list
  - Chromosome 1p-/19q- (e.g. glial tumors), deletion analysis
- Revised 81403 Molecular pathology procedure level 4: analyses added to list
  - Human erythrocyte antigen gene analyses, common variants
  - RHD deletion analysis
  - RHD deletion analysis performed on cell-free fetal DNA in maternal blood
- Revised 81404 Molecular pathology procedure level 5: analyses added to list
  - MPV17 duplications/deletion analysis
  - PIK3CA targeted sequence analysis
- Revised 81405 Molecular pathology procedure level 6: analysis removed from list
  - Cytogenomic constitutional targeted microarray analysis of the X chromosome
  - Mitochondrial genome deletions

**Genomic Sequencing Procedures (GSP) and Other Molecular Multianalyte Assays**

A new subsection was added to report DNA and RNA sequence analysis methods that simultaneously assay multiple genes or genetic regions relevant to a clinical situation. The technology used is next generation sequencing (NGS) or massively parallel sequencing (MPS) but may also be polymerase chain reaction (PCR) methods and microarrays. These codes are only used with all components of the descriptors and are fulfilled regardless of the technology used. If all components are not performed you would use the individual Tier 1 or Tier 2 codes, or the unlisted molecular pathology code 81479. There are 21 new codes; please refer to the 2015 CPT Book for complete details.

CMS has not assigned any RVU values to these new codes and will be using Gapfill to calculate future RVUs. Gapfill is a process used by CMS to allow the local Medicare Carriers (e.g. National Government Services) to define their own pricing. Over the next year CMS will analyze the claim history to determine RVU values.
Multianalyte Assays with Algorithmic Analyses (MAAA)
Guidelines have been updated to help clarify the differences between MAAAs and the new subsection of Molecular Pathology GSPs. The analysis performed must fulfill the code descriptor and if it is proprietary, it must be the test represented by the proprietary name listed in Appendix O. If these requirements are not met, use unlisted MAAA code 81599.

If procedures such as microdissection (88380, 88381) are required prior to cell lysis, these should be reported separately. There is one new CPT code in this section and several updates to the MAAA administrative codes found in Appendix O; please see Appendix O for complete descriptions.

- New 81519 Oncology (breast), mRNA, gene expression profiling by real-time RT-PCR of 21 genes, utilizing formalin-fixed paraffin embedded tissue, algorithm reported as recurrence score
- New Admin code 0006M Oncology (hepatic), mRNA expression levels of 161 genes
- New Admin code 0007M Oncology (GI neuroendocrine tumors), real-time PCR expression analysis of 51 genes
- New Admin code 0008M Oncology (breast), mRNA analysis of 58 genes
- Deleted Admin code 0005M